| 摘要 |
PROBLEM TO BE SOLVED: To provide new approaches to enhancing the in vivo efficacy of active compounds in their delivery to human and animal subjects to avoid insufficient in vivo efficacy, such as (i) low bioavailability of the active compound; (ii) undesirably short half-life of the active compound, (iii) and/or undesirably high systemic toxicity of the active compound.SOLUTION: Methods of enhancing in vivo efficacy of an active agent include administering to a subject an active agent that is coupled to a bioelastic polymer or elastin-like peptide, wherein the in vivo efficacy of the active agent is enhanced as compared to the same active agent when administered to the subject not coupled to (or not associated with) a bioelastic polymer or ELP. |
